Ernexa Therapeutics (NASDAQ:ERNA) Prioritizes ERNA-101; ERNA-201 Shows Preclinical Signal
Ernexa will concentrate resources on advancing ERNA-101 toward a planned IND in Q4 2026, after ERNA-201 showed preliminary disease-modifying activity in a collagen-induced arthritis model. ERNA-201 spend is paused; initial ERNA-101 clinical data are expected in Q4 2027.Material DetailsContext by AI…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.